Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left">Time</td><td class="align_center">SVR</td><td class="align_center">95% CI</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">End of treatment response</td><td class="align_center">103/103 (100.0%)</td><td class="align_center">100.0–100.0</td></tr><tr><td class="align_left">Sustained virological response (12 weeks after treatment)</td><td class="align_center">100/103 (97.1%)</td><td class="align_center">93.2–100.0</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Virological response of studied patients.</div>

Advances in Virology

tab3

Table 3

Table 3: Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure 